-
Mashup Score: 0
Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment. | Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment. The U.S. regulator has endorsed Beqvez for adults with the bleeding disorder hemophilia B. It becomes the first FDA-approved gene therapy for Pfizer, which will charge $3.5 million for the single-dose drug.
Source: www.fiercepharma.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 4The top 20 pharma companies by 2023 revenue - 9 day(s) ago
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing sales of its diabetes and obesity treatments Ozempic and Wegovy. Accounting for the changes at the high and low ends of the rankings were plummeting sales of COVID-19 products. | 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4The top 20 pharma companies by 2023 revenue - 9 day(s) ago
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing sales of its diabetes and obesity treatments Ozempic and Wegovy. Accounting for the changes at the high and low ends of the rankings were plummeting sales of COVID-19 products. | 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0The top 20 pharma companies by 2023 revenue - 10 day(s) ago
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing sales of its diabetes and obesity treatments Ozempic and Wegovy. Accounting for the changes at the high and low ends of the rankings were plummeting sales of COVID-19 products. | 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Two-thirds of top 20 pharmas have banned ChatGPT—and many in life sci call AI ‘overrated,’ survey finds - 12 day(s) ago
As industries around the globe wrestle with where and how often artificial intelligence (AI) should be implemented in their workflows, biopharma, for one, is proceeding with caution. | As industries around the globe wrestle with where and how often artificial intelligence should be implemented in their workflows, biopharma, for one, is proceeding with caution.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Pfizer’s latest ‘Dear Scientist’ video stars a long COVID patient looking for answers - 13 day(s) ago
As COVID-19 moves into an endemic phase, though rates of coronavirus infections and hospitalizations continue to fall, cases of long COVID appear to be slowly ticking upward. | As COVID-19 moves into an endemic phase, though rates of coronavirus infections and hospitalizations continue to fall, cases of long COVID appear to be slowly ticking upward.
Source: www.fiercepharma.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study - 20 day(s) ago
One hallmark of the FDA’s accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials. | Many cancer meds approved under the FDA’s accelerated approval pathway from 2013 to 2017 didn’t improve overall survival after more than five years of follow-up research, the study found.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 9As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake - 21 day(s) ago
About 15 years ago, Carl Ola Landgren, M.D. Ph.D., noticed an encouraging yet potentially concerning trend in the treatment of multiple myeloma. | At an FDA advisory committee meeting this Friday, two teams will present their studies examining the utility of minimal residue disease (MRD) as a potentially approvable endpoint in multiple myeloma. For this report, Fierce Pharma spoke with experts to learn about what’s at stake, including the need to bring new treatments to patients earlier.
Source: www.fiercepharma.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
Last year closed with a flurry of big-money biopharma deals. Of the industry’s top 10 acquisitions, six came in the fourth quarter. | Market research by McKinsey found that smaller, strategic M&A deals provide greater shareholder returns than multibillion-dollar acquisitions. Analysts from McKinsey and Project Farma explain why and offer advice on how to optimize deals.
Source: www.fiercepharma.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 0Inclusive Innovation: Key to the Future of Healthcare - 23 day(s) ago
By Rajni Samavedam | Inclusive Innovation: Key to the Future of Healthcare
Source: www.fiercepharma.comCategories: General Medicine News, Future of MedicineTweet
Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose https://t.co/gmoQBsslB8